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Abstract
This review discusses rational design of particles for use as therapeutic vectors and diagnostic
imaging agent carriers. The emerging importance of both particle size and shape is considered, and
the adaptation and modification of soft lithography methods to produce nanoparticles is
highlighted. To this end, studies utilizing particles made via a process called Particle Replication
In Non-wetting Templates (PRINT™) are discussed. In addition, insights gained into therapeutic
cargo and imaging agent delivery from related types of polymer-based carriers are considered.
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With rapid development of new pharmaceuticals and contrast agents, the need for the
minimization of side effects in concert with simultaneous targeted delivery to specific
tissues of interest continues to expand. Overcoming barriers for effective bioavailability of
therapeutic agents has been especially challenging in the fields of gene therapy[1] and
oncology.[2] As an illustration, despite their potential for wide application, only a few
antisense oligonucleotides or small interfering RNA’s (siRNA) have entered clinical trials.
The prevalence of hydrophobic drugs also necessitates the use of nanocarriers; for these
systems, direct dissolution in the bloodstream is limited without the formation of a salt or
use of a delivery vector.[3] One solution to this problem is the delivery of drugs, gene
therapy agents, and imaging contrast agents via nano-scale vectors, and this has been an area
of intense study for decades. Although multiple approaches have been explored and strides
have been made in therapeutic drug delivery and diagnostic imaging agent carriers, a set of
rules for the rational design of nanocarriers has not yet been fully established due to limited
understanding of how all of the carrier properties (including size and shape as well as matrix
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functionality, porosity, flexibility, and surface chemistry) interact. Clearly, a strong
motivation for the development of nanocarriers exists in cases in which the drug or imaging
agent is too fragile, insoluble, or toxic for direct in vivo administration.
The term “nanoparticle” is broadly applied in the description of almost every pharmaceutical
carrier or imaging agent system, so further classification is needed for clarity. One group of
nanoparticles is comprised of organic macromolecules including single chain thermoplastic
polymer-drug conjugates[4,5] thermoplastic polymer colloids prepared via techniques such
as emulsion polymerization,[6–9] crosslinked nanogel matrices,[10–12] dendrimers[13,14],
and carbon nanotubes.[15] For this group of materials, the carrier matrix is a single synthetic
molecule with covalent bonds and a relatively large molar mass. Other types of drug
delivery vectors often termed nanoparticles are comprised of self-assemblies of smaller
molecules which are aggregated through intermolecular forces. Liposomes[16–18] and
polyplexes[19–22] are the most studied of this class of particle, but this class of carriers also
includes aggregates such as polymersomes[23,24] and other assemblies of block
copolymers,[25] colloidosomal aggregrates of latex particles,[26,27] and protein or peptide
assemblies such as Abraxane®,[28,29] a protein-taxol assembly that has already moved
through clinical trials. The dynamic nature of these types of systems depends upon the
intermolecular forces in play and the biological conditions. Finally, as a testament to the
variety of possible approaches to this problem, nanoparticle-based therapies and imaging
agents in the pharmaceutical research pipeline include complexes based upon fullerenes,
silica,[30] colloidal gold,[31–34] gold nanoshells, quantum dots, and superparamagnetic
particles.
The potential delivery solutions of liposomal pharmaceutical carriers[17], polyplexes,
[22,35] and polymer-drug conjugates,[5,36] which have shown promise on several fronts for
decades, have been recently reviewed and will not be thoroughly elaborated upon herein.
Indeed, the breadth and volume of therapeutic and imaging nanoparticle literature is
considerable, and this review is not intended to be exhaustive. In this report, we focus on
fabrication of well-defined, nonspherical, crosslinked or linear polymer particles as vectors
for pharmaceutical and imaging agent delivery.
Rational Design of Drug and Contrast Agent Carriers
Several critical factors that must be considered in the design of contrast agent and/or
polymeric drug carriers include the chemical functionality and mechanical flexibility of the
matrix, the degree of cross-linking, if any, the dispersion or encapsulation of the drug within
the matrix, the permeability of the cargo through the matrix of the particle, the number and
the nature of phases that comprise the particle (one phase versus two or more phases e. g.
drug rich phase and matrix rich phase,) the size and shape of the particle, and the surface
chemistry. Many of these factors need to be studied and controlled in particle design for the
delivery of imaging contrast agents and the delivery and release of cargos ranging from
small molecules to proteins to nucleotides. A large body of in vivo studies has proven that
particle size is a crucial factor in biodistribution, treatment of inflammation, and tumor bed
penetration. The effect of particle shape, on the other hand, has received much less attention
and is therefore not well understood.
Using advances at the interface between biology and the traditionally materials science
based field of soft lithography,[37] researchers just recently have been able to access
interesting shapes at the sub-micron size range on a sufficient volume scale to allow for
extensive in vitro and in vivo biological studies. In this technique, a biological pattern or the
pattern on a hard substrate master, typically a silicon wafer, is embossed onto to a more
flexible, crosslinked polymer material, the mold. Soft lithography has been used extensively
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to mold naturally occurring objects and prepare patterns for microfluidics, and these topics
have been the subject of recent reviews.[38] Herein, we review recent advances in soft
lithography[37,38] as a means for producing drug delivery and diagnostic imaging particles.
A modification of these traditional lithographic methods, known as Particle Replication In
Non-wetting Templates (PRINT®) (Figure 1),[39–48] has proven to be valuable for
producing precisely-controlled polymeric vectors in the tens of nanometers to micron size
range. The PRINT process constitutes a tunable particle preparation platform by allowing
entrapment (transiently, if desired) of diagnostic imaging agents and a wide variety of
therapeutic cargo types while simultaneously providing tremendous latitude in the chemical
composition of the carrier matrix. In addition, the PRINT process is well suited for
independent and precise variation of shape, size, and modulus (stiffness) of the particle.[49]
Indeed, PRINT affords unprecedented control and flexibility in the engineering of rationally
designed particles, and thus it offers advantages as a fabrication method when compared to
techniques employed to prepare traditional carriers such as liposomes, dendrimers, and
colloidal particles.
Particle Size and Shape Effects
Until recently, the general conclusions drawn about particle size effects on various
biological processes relied on studies using primarily spherical particles. This is due to the
fact that drug or contrast agent-loaded spherical particles with a narrow size distribution can
be fabricated in a straight forward manner by a number of methods including emulsion,
dispersion, and suspension polymerizations as well as precipitation and spraying techniques.
The roles that particle size and composition play in biodistribution,[52] cellular binding,[53]
cell entry pathways,[54] cell uptake,[55–57] and tumor bed penetration[58,59] have been
extensively studied for macromolecular carriers and spherical particles.
This work with spherical particles has resulted in valuable insights, but many naturally
occurring objects are non-spherical, and biological processes typically occur under dynamic
conditions in which the motion of spherical and non-spherical objects will differ. Indeed,
Decuzzi and Ferrari’s theoretical work predicts that, under conditions of linear shear flow
such as that in the bloodstream, oblate particles adhere more strongly to biological substrate
than spherical particles; use of non-spherical particles for delivery is predicted to improve
therapeutic and imaging efficacy.[60] Experimentally, the combined effects of particle size,
shape, charge, and chemical composition on biodistribution and cell entry have not yet been
fully elucidated,[61] but data suggest that seemingly small changes in chemical composition
and modulus of the particle materials can have profound effects in vivo. Clearly the major
roadblock to elucidating the interdependence of particle size, shape, surface chemistry, and
modulus is the previous lack of a suitable particle fabrication technique.
Recently, techniques have been developed to prepare non-spherical particles by molding
techniques such as the PRINT process, post-fabrication manipulation of spherical particles,
or directly through microfluidics. Although particle size impact on bioavailability has been
the subject of numerous studies, particle shape, on the other hand, has received less
attention. Clearly shape is crucial to the particle’s mechanism of cell entry[44,62,63] and the
release rate of the therapeutic cargo.[64,65] Shape effects on biological processes are still
not fully understood, particularly at the nanoscale, primarily due to past limitations in the
control of particle fabrication. The work exploring shape effects in vitro and in vivo is
detailed in the sections below and summarized in Table 1. Experimental explorations into
the idea that unpredicted biological effects could result from non-spherical particle shapes
are described in this section.
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Top Down Methods for Shape-Specific Particle Fabrication
The PRINT Process—Crosslinked fluoropolymers have recently been employed as
alternative materials to poly(dimethyl siloxane) (PDMS) for microfluidics[51], as molds for
imprint lithography,[49,60] and as a template for particle design and synthesis via the
PRINT process.[40] PRINT is unique over the imprint lithography techniques promulgated
by Whitesides et al. in that PRINT uses elastomeric fluoropolymers instead of silicones
which results in three distinct features not possible with silicones. First of all,
perfluoropolyether elastomers have a lower surface energy which enables the selective
filling of nano-scale cavities in the mold using any organic liquid—without wetting the land
area around the cavities—which enables distinct objects or particles to be formed at the
micro- and nano-scales without the formation of the interconnecting “flash layer” noted as a
major hurdle in traditional imprint lithography.[69] Secondly, organic liquids and sol-gel
metal oxide precursors do not swell fluoropolymers like they do silicones, so one can make
PRINT particles and particle arrays having a wide range of attributes (surface chemistries,
degradation characteristics, deformability). Thirdly, the Teflon™-like characteristics of the
fluoropolymer mold allows the resultant organic particles to be easily harvested or removed
from the mold. Indeed, photocurable perfluoropolyethers (PFPEs) used in the PRINT
process retain the advantageous flexibility of PDMS while imparting an even lower surface
energy and exhibiting dramatically improved solvent resistance.[50,51] The PFPE molding
materials, which in the uncured state have low viscosities and positive coefficients of
spreading on most substrates, have been shown to precisely mold even fragile or “soft”
nanoscale objects such as block copolymer micelles and naturally occurring objects such as
viruses.[41] Rogers and co-workers have recently published a side-by-side comparison of
PDMS versus PFPE-based materials in soft-lithography.[70]
Perhaps the biggest potential drawback of fluorinated molding matrices when compared to
silicone materials is cost. This disadvantage has been mitigated by the development of
continuous mold manufacturing processes that employ an inexpensive backing material
coated with a very thin film of the fluorinated molding material (Fig. 2).[71] This
engineering advancement for rapid, economically feasible mold replication has taken the
PRINT process from the realm of an academic method to reproduce small features to a
scalable particle manufacturing process.
Using the PRINT process, particles have been constructed from matrices ranging from
synthetic materials such as highly crosslinked hydrogels and linear polyesters[40,42] to
natural materials such as pure, biologically relevant proteins (Fig. 3).[48] The PRINT
process can be adapted as needed to provide appropriate conditions for mold cavity filling
and subsequent solidification of the particles using diverse processing techniques such as
lyophilization, solvent evaporation, thermal curing/annealing, photocuring, vitrification, or
crystallization. Particles made via the PRINT process have been shown to be effective
delivery agents for both therapeutic cargos and imaging agents.[46,47] For example, a
reductively labile crosslinker was incorporated into hydrogel particles in the micron-size
range fabricated via the PRINT process, and these particles effectively delivered
doxorubicin to cervical cancer cells (HeLa cells.)[47] One of the key advantages of the
PRINT process is the ability to precisely control particle size and shape in the nanometer-
size regime independently of composition. The impact of this aspect of the technology is
expanded in the next sections.
Biodistribution and Cell Uptake of PRINT Nanoparticles—A preliminary study of
the biodistribution and pharmacokinetic study of [125I]-labeled non-targeted, cylindrical
particles prepared by the PRINT process in the 200 nm size range in healthy mice showed
the expected uptake primarily in the liver and spleen.[43,45] The conventional strategies to
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reduce the rapid clearance from the bloodstream and uptake by the liver and spleen have
been to increase hydrophilicity of the particle surface and reduce particle size. In an
alternative approach, however, Geng and coworkers have compared soft spherical
assemblies with flexible filaments and found that the in vivo circulation time for the non-
spherical filomicelles was about ten times longer than their analogous spherical
counterparts.[66] They extended their study to the delivery of paclitaxel and showed
significant tumor shrinkage in a xenograft mouse tumor model, and showed that an increase
in the filomicelle length had the same relative therapeutic effect as a similar increase in the
paclitaxel dosage. These results show that, in applications where a prolonged circulation
time is desired, a long, worm-like structure can be more effective than a sphere.
In addition to dramatically affecting biodistribution, particle size and shape can play a key
role in the mechanism of passage through the cell membrane into the cell. The biological
details of cell internalization of macromolecules and particles have been reviewed.[72]
Gratton et al. have completed experiments showing size and shape effects on the uptake of
highly crosslinked acrylic particles fabricated via the PRINT process by HeLa cells.[44] A
large library of crosslinked, PEG-based particles of various sizes and shapes were prepared
via the PRINT process. Non-targeting particles fabricated from this formulation showed
excellent uptake by HeLa cells (Fig. 4), and cellular uptake mechanisms have been
elucidated. This work showed that, interestingly, it is not the particles of lowest volume that
enter cells at the fastest rate; rod like particles showed kinetically preferential uptake.
Step and Flash Imprint Lithography—In another study of carefully fabricated, non-
spherical particles, Roy et al. have used step and flash imprint lithography (S-FIL) to
prepare cubes as well as triangular and pentagonal cylinders (Figure 5). Drawing on a large
body of literature for enzymatically degradable peptide sequences for drug delivery,[73–76]
the authors were able to use cathepsins to trigger release of DNA plasmids from these
particles in vitro. This work combined the superior shape control provided by lithographic
techniques with clever cargo encapsulation and release strategies.
Recently Emerging PDMS-Molding Processes for Fabrication—The most widely
studied molding material is lightly crosslinked PDMS, commonly referred to as silicone
rubber. Advantages of using PDMS as a molding material are numerous and include low
toxicity, low modulus (flexibility), low surface energy which allows facile release from
master pattern templates as well as replication of molecular-scale objects,[77] and high gas
permeability, which allows dead-end filling. For some applications, however, the swelling of
PDMS molds in organic solvents and/or PDMS-fragment transfer to the sample constitute
serious drawbacks. Alternative silicone-based materials and filled molding material
formulations that minimize the mechanical distortion of the stamp have been developed.[78]
In addition, various mold surface treatments,[79,80] such as oxygen plasma and fluorosilane
grafting, have been explored in efforts to make the mold surface more hydrophilic or
hydrophobic, respectively, which has implications in both wetting during mold filling and
release of the particles from the mold. Finally, cleaning procedures have been developed
which virtually eliminate sample contamination by small fragments from the PDMS-stamp.
[81]
With the target application of drug delivery, Hansford and coworkers have fabricated both
thermoplastic and thermoset microparticles and medical devices in various shapes using
PDMS stamps.[82–84] The design of unique shapes with “arms” that can self-fold to imbed
into intestinal tissue[84] after oral delivery highlights the vast possibilities opened by the
tools for precise shape control on the micron and nanometer size regimes. This group also
prepared microcapsules for intravenous delivery containing sucrose as a model cargo with a
thin poly(vinyl alcohol) (PVA) or poly(lactic-co-glycolic acid) (PLGA) based skin that
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swells in the presence of water due to osmotic pressure. In this case, release of the drug is
dominated by diffusion out of the microcapsules through the thin membrane rather than
dissolution of the thermoplastic matrix, so an entirely new drug transport profile is
accessible. This offers some advantages over the use of conventionally prepared PGLA
microspheres and nanoparticles,[85] such as a relatively high capacity for drug loading.
In another application of PDMS-based soft lithography to drug-carrier fabrication,
Oudshoorn and co-workers have explored the use of various molding techniques including
rigid micromolding, soft micromolding, and photolithography to prepare uniform
microparticles comprised of methacrylated hyperbranched polyglycerols.[79] They obtained
high yields of squares and hexagon shapes in the tens to hundreds of microns size regime,
but, in the PDMS-based molding experiments, they noted that a number of particles had less
well defined shape than they obtained using a rigid, epoxy-based micromold. Clearly,
traditional soft lithography using PDMS-based molding materials offers wide latitude in the
design of size and shape-specific particles, particularly on the micron size scale, and it
constitutes an interesting research path toward delivery and imaging applications. However,
for applications such as intracellular drug delivery and imaging where nanoscale vectors are
often most efficacious, opportunities exist to improve on PDMS-based soft lithography
using alternative molding techniques.
Other Methods for Shape-Specific Particle Fabrication
Because particles used for imaging and drug delivery are generally < 5 microns in their
largest dimension, they are comparable in size to the pathogens combated during the
evolution of the immune system.[86] Micron-sized range particles (0.5 μm and larger) have
been described as invoking “bacteria-like responses,” primarily being removed from
circulation via phagocytosis, while nanoparticles up to 200 nm in diameter are more likely to
invoke “virus-like responses.”[86] Exploiting this trend, nanoparticles have been
intentionally designed to either invoke, suppress, or avoid the immune response.[87]
Pronounced invocation of the immune response has driven size-dependence research in
particulate vaccine vectors (adjuvants),[88–90] suppression of an immune response could
make particulate carriers useful during organ transplant therapy, while avoidance of the
immune system and reduced systemic toxicity using targeted particulate carriers is most
often desirable in the case of imaging and therapeutic agents.
The emerging understanding of the importance of particle shape in phagocytosis has been
described and carefully studied by Champion et al. (Figure 6). [62,63] Recognition of the
fact that naturally occurring immunological targets vary widely in both size and shape
provided motivation for this work. By carefully varying shape at constant size, the authors
concluded that it is indeed particle shape, rather than size, which plays a dominant role for
determining the complexity of the local actin structure, and ultimately whether phagocytosis
or simply spreading processes occur.
In summary, numerous studies have shed light on the roles played by size and shape of
particulate carriers in the complicated biological processes of biodistribution, cell uptake,
and bioavailability. The ability to prepare particles in a manner than allows independent
alteration of one variable at a time has proven fruitful for gaining insights into shape-
dependent biological processes such as phagocytosis. Many techniques, such as stretching
thermoplastic particles[62] or S-FIL preparation of crosslinked particles as described above,
[68] can be employed to prepare small amounts of shape-specific particles. Practical, large-
scale manufacturing techniques for fabrication of non-spherical, shape-specific particles
constitute perhaps the biggest advantage gained by the application of the PRINT process to
this area.
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While size and shape clearly play an important role in nanoparticle drug delivery, the field
of medical imaging has seen very few applications or systematic studies exploring the effect
of variation in particle size and shape. Therefore, the potential for important discoveries in
the field of size and shape dependence on nanoparticle biodistribution and targeting is
enormous. Without a doubt, studies directed toward successful targeted delivery of size and
shape-specific nanoparticles as novel therapeutic agents will be contingent on the successful
visualization of their whereabouts in vivo. Moreover, nanoparticle-mediated delivery
provides an opportunity to reduce the toxicity effects associated with commonly employed
contrast enhancement agents.
A number of different imaging modalities can be drawn upon for successful imaging of
tissue via this new class of particles including, but not limited to, magnetic resonance (MR)
imaging, positron emission tomography (PET), single photon emission computed
tomography (SPECT), ultrasound imaging, and fluorescent imaging. Here we focus on
recent advances for imaging agent carriers in MR and PET imaging.
MR Imaging
Magnetic Resonance (MR) imaging plays an ever increasing role in the development of
targeted nanoparticle therapeutics and imaging agents because of its high spatial resolution
and unparalleled imaging of soft tissue. Using conventional contrast agents such as iron
oxide nanoparticles and small molecule gadolinium (Gd) chelates, MR imaging is capable of
providing excellent spatial resolution and 3D anatomical information. Because of its low
sensitivity, however, relatively large concentrations of contrast agent are required to observe
a modest increase in contrast (especially for T1 weighted imaging). The potential side
effects (such as nephrogenic systemic fibrosis or NSF) caused by these relatively large
contrast agent doses have spurred interest in particle-mediated delivery of MR contrast
agents. These contrast agents carry multiple MR beacons per particle and are capable of
drastically improving the local contrast. Nanoparticle contrast agents are paving the way for
a new generation of imaging in which smaller doses will be required both to monitor the in
vivo distribution of nanoparticles and to perform targeted imaging of diseased tissue and
tumors. Some of the most recent efforts to exploit polymer-based nanoparticles for delivery
of iron oxide and Gd, respectively, are summarized below, and then initial efforts to apply
the PRINT process to this problem are detailed.
In many respects, iron oxide nanocrystals are close to ideal nanoparticle contrast agents.
They are nontoxic and are easily surface functionalized with stealthing and targeting agents.
[91] Monodisperse samples of iron oxide nanocrystals have been shown to have different R1
and R2 relaxivities based solely on crystal size[92] as well as on the surface coating.[93]
Spherical micelles of poly(styrene-b-acrylic acid) containing multiple iron oxide
nanoparticles were recently reported by Taton and coworkers.[94] The micelles were surface
crosslinked into a covalently bound assemblies in the 40 – 140 nm size range using a
diamine and functionalized further with a fluorescein derivative. Using this method, larger
polymer particles necessarily contained a larger number of iron oxide particles. A different
method recently reported by Sailor et al. describes improved relaxivity and improved
targeting of tumor cells over traditional iron oxide nanoparticles using nanoworms.[95] The
worms were composed of iron oxide nanoparticles trapped in strands of dextran.[95] The
authors believe that the unique shape of the elongated particles is the key to improving their
efficacy.
Herlihy et al. have fabricated 200 × 200 nm cylindrical and 2 × 2 × 2 μm cubic particles of a
biocompatible hydrogel matrix containing iron oxide nanoparticles via the PRINT process
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(Figure 7).[46] This constitutes the first example of shape and size specific magnetic
hydrogel particles produced by a lithographically-based process. They were able to
systematically control the iron oxide content without altering the size or shape of the
particles. Increasing the cargo content led to a decrease in signal intensity in T2 weighted
phantom studies.[46] Since the cargo content for particles fabricated via the PRINT process
can be controlled independently from the particle’s shape, size, and surface functionality,
this provides a unique opportunity to tune the signal intensity without affecting other key
factors such as biodistribution.
As stated earlier, iron oxide based imaging agents are popular because of their low level of
toxicity and the ease with which one can modify their surface with a variety of ligands,
stealthing polymer coatings and fluorescent beacons for multimodal imaging. However,
because the majority of iron oxide contrast agents create a decrease in signal intensity,
causing tissue containing the contrast agent to “go dark,” researchers have pursued other
compounds for contrast agents that increase signal intensity.
Small molecule chelates of Gd such as Gd-DTPA (diethylenetriaminepentaacetic acid) and
Gd-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and their derivatives
create an increase in MR signal intensity. Caravan has described how the limited sensitivity
of MR requires millimolar concentrations of these agents before any contrast is observed.
[96] Coupling multiple Gd chelates to a single nanoparticle carrier can increase contrast
enhancement. A number of synthetic approaches towards gadolinium-bound particles have
been described including crosslinked micelles,[97] peptide containing liposomes,[98]
dendrimers,[99] and hybrid systems.[100]
Very few examples are found of shape and size specific nanoparticles containing
gadolinium. One approach involves the encapsulation of MR contrast agent within a
nanocapsule. Landfester et al. demonstrate the use of inverse miniemulsions to encapsulate
commercially available gadolinium-containing contrast agents inside crosslinked dextran
nanocapsules.[101] The capsules are porous in nature allowing water exchange across the
surface. While the nanocapsules show a small reduction in relaxivity from that of the small
molecule encapsulated within, the crosslinked dextran coating provides potential for surface
functionalization and altered biodistribution.
Recently Herlihy et al. demonstrated the first example of Gd-containing shape and size
specific particles for MR imaging (Figure 8).[67] Two sets of biocompatible hydrogel
particles, 200 × 200 nm cylinders and 2 × 2 × 2 μm cubes encapsulating a commercially
available Gd contrast agent (Omniscan™), were administered to healthy mice. Particle
biodistribution was different depending on the size of the particles. The small particles
created an increase in contrast in the liver, kidney and blood vessels while the larger
particles were observed mostly in the liver and blood vessels. Increased contrast was
observed up to 3 hours after injection.
Position Emission Tomography (PET)
A number of groups have also adopted a nanoparticle platform for imaging using positron
emission tomography (PET). PET relies on radioisotopes that can easily be bound to the
surface, or interior, of a nanoparticle using simple chelation chemistry. Positron emitters
such as 64Cu are detectable at concentrations as low as picograms per milliliter. The high
sensitivity of PET makes it ideal for quantitative data analysis. Some limitations of PET
include low spatial resolution, the inability to provide significant anatomical information,
and need for contrast agents that are not widely available.
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Work performed by Gratton et al. showed the first example of shape and size specific
nanoparticles bound to 64Cu-DOTA for use in in vivo PET imaging (Figure 9).[45] To make
these particles, DOTA-NHS-ester was bound to the surface of a 200 × 200 nm cylindrical,
biocompatible hydrogel particle. DOTA is widely popular for binding radioisotopes such
as 64Cu to polymers. The particles were sterically stabilized with high molecular weight
PEG. Similar to the 200 nm particles used for MR, and supporting other biodistribution
studies,[44] the particles containing 64Cu appeared to accumulate in the liver.
In 2007, Wooley et al. reported the optimization of radiolabeling crosslinked micellar
assemblies polystyrene-b-poly(acrylic acid) with 64Cu-DOTA.[102] In this work, a DOTA-
lysine derivative is covalently bound to the acrylic acid units of the copolymer that is
subsequently labeled with 64Cu. The copolymers were then used to form micelles and were
surface-crosslinked using 2,2′-(ethylenedioxy)-bis(ethylamine). By varying the relative
amounts of DOTA-lysines per chain and the crosslinking ratio they were able to optimize
signal enhancement as high as 400μCi/μg. Interestingly, the researchers found that the non-
crosslinked micelles provided the most intense signal but pointed to the necessity of surface
crosslinking for stable nanocontrast agents.
Using a surface crosslinked platform similar to the one described earlier, Wooley and
coworkers[97] made 40 nm “knedel-like” particles with high relaxivities (39−1 mM−1). The
high relaxivity was attributed to the slow rotation of the particle. In this work the particles
were composed of assemblies of poly(acrylic acid-b-methyl acrylate) surface crosslinked
with the same diamine. The particles were functionalized with a
diethylenetriaminepentaacetic acid (DTPA) derivative that coordinated gadolinium.
Nanoparticle platforms such as these may be useful in the future as molecular imaging
agents.
Conclusion
In summary, nanoparticle mediated delivery of therapeutic and contrast agents constitutes a
growing field of research. New techniques for independently controlling particle size, shape,
composition, cargo loading, and surface functionality are beginning to pave the way for
understanding the complicated interplay between these particle parameters and biological
systems.
We have reviewed a number of studies in which polymer-based nanoparticles have been
used as carriers for therapeutics and imaging contrast agents. Striking recent studies from a
couple of different research groups have indicated that anisotropic, worm-like particles can
enhance circulation time in comparison to previous studies with spherical particles. In
addition, soft lithography methods, such as the PRINT process, are becoming valuable tools
in the repertoire of techniques for imparting size, shape, and composition control. With this
new capability, identical size and shape particles have been prepared for a number of
different functions from delivery of small molecule chemotherapeutics to imaging kidneys.
Moreover, independent variation of particle shape at constant composition has shown shape
to be critical in areas such as cell entry kinetics.
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Schematic representation of the PRINT process. a.) Empty mold (green), high surface
energy polymer sheet (clear), roller (black) is brought into contact with the particle
precursor solution (red) and the mold; b.) Roller evenly distributes particle precursor
solution into the cavities of mold. Excess particle precursor solution is wicked away by the
high surface energy polymer sheet; c.) Particles are cured in the mold; d.) Particles are
removed from the mold; e.) Particles are collected or harvested using a number of different
film based techniques and ultimately are dispersed in solution.
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Continuous thin mold manufacturing for the PRINT process. Patterned surface can be seen
in green.
Reprinted with permission from Liquidia Technologies.[71]
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SEM images of particles of various sizes, shapes, and compositions prepared via the PRINT
process: (A) Hydrogel rods containing antisense oligonucleotide; (B) crosslinked degradable
matrix cubes containing Doxorubicin HCl; (C) Abraxane™ harvested onto medical adhesive;
(D) Insulin particles harvested onto a medical adhesive; (E) Hydrogel “boomerangs”
containing 15 wt% iron oxide; (F) Hydrogel cylinders containing 10 wt% Omniscan™.
Reprinted with permission from references (B) [47];(C) [48]; (D) [48]; (E) [46].
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TEM showing HeLa cell internalization of 150 nm × 450 nm (top) or 200 nm × 200 nm
(bottom) cylindrical particles fabricated via the PRINT process.
Reprinted with permission from [44].
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SEM images of S-FIL imprinted (100% w/v, MW 3400) PEGDA nanoparticles: (A) 50 nm
squares (scale bar = 100 nm), (B) 100 nm squares (scale bar = 200 nm), (C) 200 nm squares
(scale bar = 300 nm), (D) 200 nm triangles (scale bar = 200 nm), (E) 400 nm triangles (scale
bar = 300 nm), and (F) 400 nm pentagonal particles (scale bar = 200 nm).
Reprinted with permission from [68]
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a) Scanning electron micrographs and 3D illustrations of PS particles created for
phagocytosis experiments. (A) Spheres. (B) Oblate ellipsoids (13%). (C) Prolate ellipsoids
(7%). (D) Elliptical disks (9%). (E) Rectangular disks (5%). (F) UFOs (12%). Particles are
monodispersed with average standard deviations of measured dimensions for each shape
listed in parentheses. A portion of this variation is due to 2–5%standard deviation in the
diameter of spheres used as starting materials. (Scale bars: 5 m.)
Reprinted with permission from [62]
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Magneto-polymer composite polymer particles of well defined size and shape prepared via
the PRINT process: (A) SEM image of 200 nm × 200 nm cylinders, (B) SEM image of
2×2×2 micron cubes (C) TEM of biocompatible 200 × 200 nm particle containing 15 wt%
PEG-silane coated iron oxide nanocrystals, and (D) T2 phantom study of iron oxide
containing particles in agarose gel. Equimolar concentrations of PRINT particles with
increasing iron oxide loading.
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T1 weighted MR images a bolus injection of 200 × 200 nm cylindrical particles (a) just
before (b) and 60 minutes post (c) injection.
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MicroPET imaging with 64Cu-DOTA PRINT particles. Time resolved PET images
consisting of a two hour dynamic scan. The PET/CT images are overlayed. Mouse was
injected with 136.2 μCi of 64Cu-labeled DOTA-nanoparticle. Both the coronal view (top),
and sagittal view (bottom) are presented.
Reprinted with permission from [45]
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Table 1
Recent Studies Elucidating Shape Effects on Polymer Nanoparticle-Mediated Drug Delivery and Therapeutic
Imaging Applications
Particle Matrix and Description Size Range Studied Shape Reference
PEG-based Diblock copolymers 22–66 nm × 0.5–8 μm Spheres vs. flexible filaments [66]
Polystyrene 1–10 μm Spheres, oblate or prolate ellipsoids,
elliptical discs, rectangular discs, “UFO’s”
[62,63]
Degradable and non-degradable PEG-based hydrogels 100 nm – 5 μm Cubes, cylinders, rods [44–46,67]
Degradable peptide diacrylates gels vs. Non-
degradable PEG-based hydrogels
50–400 nm Squares, triangle, pentagons [68]
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